Full Press Release Details
| TO OUR STOCKHOLDERS, | APDN Highlights | |
| In the world today, our DNA authentication solutions are more relevant than ever. In 2008 global markets suffered from massive increases in product tampering, IP infringements, adulterations and outright counterfeits. The victims are consumers, corporations and governments alike. The impact is not virtual, but measured in lives lost, stolen revenues, devalued brands, diminished quality and heightened insecurity. We believe Applied DNA Sciences offers the most viable authentication solutions available to curb these threats. The marketplace is beginning to hear us; our product offerings are gaining traction each month; our quality promise has been tested and realized; our revenues are growing each quarter. We have reported our fourth consecutive quarter of revenues, with our last three quarters averaging 30% growth quarter-over-quarter. This year, we have manufactured over 1000 unique SigNature DNA markers for a broad spectrum of customers; many of those DNA sequences have the potential to generate annuities for years to come. Applied DNA ("APDN") has begun to deliver commercial solutions, and our investors and society should benefit. Applied DNA in the Global Marketplace The Applied DNA story is largely intertwined with a global marketplace, driven primarily, by the enhanced need for safety and security. Each time a product changes hands in its path to the market, mistrust in the authenticity of the product increases. The anti-counterfeiting market has been largely shaped by the media, by reporting on contaminated or adulterated goods, rather than the ways to authenticate genuine products in the supply chain in order to ensure consumer confidence. Most of our competitors emphasize only the deterrent value of their technology. Going beyond deterrence, APDN's strength is sustained from the front end - marking the physical product, to the back end - authentication of a forensic DNA sequence that uniquely identifies a single item. | Four consecutive quarters of increased revenues Over 1,000 unique SigNature DNA markers developed for customers in multiple global markets Broadened product lines comprised of SigNature DNA, BioMaterial Genotyping, BioActive Ingredients build upon our strategy of diversified revenue sources with managed risk concentration and shortened sales cycles Improved detectability and authentication processes for DNA providing better in field recovery and controls Auditable processes and controls implemented throughout the company to support authentication and security to our customers Expanded patent and trademark portfolios which will form the basis for added value through future licensing revenue opportunities Growing convergence of public awareness of APDN's DNA Authentication technologies as a credible means to protect genuine products and consumer safety and well being . | |
| This year, APDN broadened its commercial scope to best position us to ultimately capture the lion's share of the opportunities available to DNA-based authentication. SigNature DNA, our central platform that uses botanically derived genomic DNA sequences as proof of originality was deployed in a new industry vertical, cash-in-transit. We have increased our penetration into the markets for secure inks, labels, event ticketing, and branding in general. |
Letter - November 2008 - Page 1
Letter - November 2008 - Page 2
Letter - November 2008 - Page 3
Letter - November 2008 - Page 4
Letter - November 2008 - Page 5
Letter - November 2008 - Page 6
Letter - November 2008 - Page 7
| This year we worked with Cameron Associates and SmallCapNetwork.com to enhance our Investor Relations, in addition to maintaining relationships with prior IR firms. We recognize the need to improve our Investor Relations activities and will continue to increase our efforts as our resources permit. Recent efforts resulted in our invitation to present at the annual Homeland Security Investor conference in Washington, DC, sponsored by Imperial Capital. Looking Ahead We believe in the strength of our DNA Authentication platforms and our growing BioActive Ingredients business and we are confident in our strategy as we get closer to profitability. Specifically, in the short term we are focused on growing and executing on sales, without expanding operating costs, so that we cross the profitability barrier as quickly as possible. We remain committed to tight fiscal governance and anticipate continued quarterly revenue growth over the next year as we build on the strengths of our core businesses and partnerships. We are confident that many of the positive developments that we have made will come to fruition in 2009. We have made significant progress toward our goals and we believe our vision and strategy will take us there, as demonstrated by our achievements thus far. Your ongoing support is instrumental to the long-term health and success of our company. We wish to thank you for your continued support and commitment to Applied DNA Sciences. | The statements made by Applied DNA Sciences, Inc. may be forward-looking in nature and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements describe the Company's future plans, projections, strategies and expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of Applied DNA Sciences, Inc. Actual results could differ materially from those projected due to changes in interest rates, market competition, changes in the local and national economies, and various other factors detailed from time to time in Applied DNA Sciences' SEC reports and filings, including our Registration Statement on Form S-1 as amended and Annual Report on Form 10-KSB, filed on January 15, 2008, our subsequent Quarterly Reports on Form 10-QSB, and our Current Reports on Form 8-K. The Company undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date hereof. | |
| 25 Health Sciences Drive | ||
| /s/ James A. Hayward | Stony Brook, NY 11790 | |
| James A. Hayward | t 631-444-6370 f 631-444-8848 | |
| November 2008 | info@adnas.com www.adnas.com |
Letter - November 2008 - Page 8